All In Biotech

Drug Trial Radar · NCT07584057

An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia

An Open-label, Multicenter Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

146

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Feb 2030

Study completion Mar 2030

Sponsor

Lead sponsor
Yunnan Baiyao Group Co., Ltd.Industry
Sponsor type
Industry
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, multiple-dose Phase I/IIa clinical study to assess the safety/tolerability, PK characteristics,immunogenicity, and preliminary efficacy of INB301 Injection in patients with cancer cachexia. The indication to be explored for Phase I is malignant solid tumor with cachexia; Phase IIa will determine the specific study cohort after discussion between the investigator and the sponsor based on the previously obtained clinical trial data and the benefit/risk ratio of the subjects, and preliminarily consider 3 cohorts of tentative 20-30 patients each, including non-small cell lung cancer, pancreatic cancer and colorectal cancer with cachexia.

Conditions

  • Cancer Cachexia

Interventions

  • INB301 InjectionBiological

    The screening will be completed within 28 days before administration. Subjects who pass the screening will receive subcutaneous injection of INB301 until the investigator determines that the risk of continued treatment outweighs the benefit, toxicity becomes intolerable, or other criteria for withdrawal or treatment discontinuation are met, whichever occurs first. The end-of-study/early withdrawal visit will be completed at 28 days (±7 days) after the last dose. Each 1 mL of INB301 Injection contains 100 mg of the drug, and 2 mL of the drug can be injected at each subcutaneous injection site, which is at the left and right abdominal subcutaneous tissue, as well as the left and right arm subcutaneous tissue. The specific dose is determined according to the dose cohort. Dosing every 3 or 4 weeks is proposed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Through study completion, an average of 1 year.
  2. Mean change in body weight from baseline during each assessment period within 12 weeks.Time frame: Through study completion, an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 52 Fucheng Road, Haidian District

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.